Recently, Merck announced that its product Zesuning (common name: human thyrotropin beta for injection), which is a cooperation product with local innovative enterprise Zejing Pharmaceutical, has been officially approved by the State Drug Administration of China. Zesu Ning is the first innovative product approved for precise postoperative evaluation of differentiated thyroid cancer. This drug is used for collaborative diagnosis of differentiated thyroid cancer patients in follow-up after total or near total thyroidectomy, aiming to achieve accurate evaluation of postoperative condition through serum thyroglobulin detection and whole-body imaging with or without radioactive iodine. Muander, head of Merck's global business unit related to medical health, said that the approval of Zesuning was the embodiment of Merck's concept of "working together for patients", and also the practical achievement of combining the global vision with China's local needs and working together with local innovation forces, which confirmed the company's efficient innovation landing capability in China and firm commitment to the market. Zesu Ning is an injection grade recombinant human thyroid stimulating hormone product independently developed by Zejing Pharmaceutical. Dr. Sheng Zelin, Chairman of Zejing Pharmaceutical, stated that as the company's fourth independently developed product, the approval of Zesu Ning marks a new stage of cooperation between the two parties. He looks forward to leveraging Merck's rich market experience and commercialization capabilities to accelerate the application of this product in China and benefit a wide range of patients. Despite the overall good prognosis and long survival time of thyroid cancer, there is still a considerable proportion of recurrence and metastasis. To address this clinical dilemma, Zesu Ning provides a new option for precise evaluation without interrupting thyroid hormone therapy. Its approval is based on a phase III clinical study conducted at 27 research centers in China. Research data shows that in terms of whole-body imaging with radioactive iodine and serum stimulated thyroglobulin detection, the consistency rates of Zesu Ning and traditional methods are 88.2% and 90.4%, respectively. When combined, the consistency rate increases to 93.6%. At the same time, using Zesu Ning can reduce the symptoms of hypothyroidism in patients and improve their emotional state. The main researcher of the study, Professor Lin Yansong from Peking Union Medical College Hospital, pointed out that the rapid implementation of Zesu Ning means that patients are expected to break free from the limitations of traditional methods and truly achieve personalized and precise postoperative management, thereby improving treatment effectiveness and quality of life. (New Society)